3 Monster Stocks to Hold for the Next 10 Years

Most of the time, most investors embrace the idea that a new stock pick should be seen as a "forever" holding. After all, it can take a lifetime for a company to deliver its full potential upside, as well as overcome any setbacks its stock may suffer in the meantime.

Every now and then, though, an investment opportunity comes along that's clearly going to sizzle only for a relatively short while, but is likely to soar during this time.

To this end, here's a look at three stocks in situations that could readily produce oversized gains over the course of the decade ahead.

1. Qualcomm

Computing processors like Nvidia's used in artificial intelligence (AI) data centers were the focal point of the first chapter of the artificial intelligence revolution. Now, the data centers themselves are the heroes (although honorable mentions should be given to generative-AI-capable mobile devices like a small number of smartphones or laptops).

Artificial intelligence's next proverbial hot button, however, is likely to be found somewhere in between ... literally. That's on the "edge," between an end user and a data center. Examples include autonomous vehicles, factory sensors, smart cities' traffic management solutions, wearables, and more. These are solutions that not only don't require a data center to manage, but technology that meets needs where it makes the most sense to meet them -- by AI-powered decision-making tech installed right where information is turned into action.

As the artificial intelligence industry matures and more designers and engineers recognize this reality, market research outfit Technavio believes the AI edge computing market is poised to grow at an annualized pace of 32% through 2029, jibing with several other outlooks.

And one company is arguably better-positioned than any other to capitalize on this growth. That's Qualcomm (NASDAQ: QCOM). Leveraging the know-how found in its AI-capable Snapdragon processors already in a handful of smartphones and laptops currently in consumers' hands, Qualcomm is now successfully adapting this tech for automobiles with driver-assistance features, security systems, industrial automation, and more.

Just don't tarry if you're interested. While QCOM shares have performed poorly of late, that's not due to a lack of demand. That's largely just due to a shortage of memory chips, crimping the purchase of most technological solutions. But this isn't a permanent bottleneck. Once it abates, Qualcomm's stock could start recovering in a hurry.

2. MercadoLibre

Do you ever wish you could go back in time and invest in Amazon in its early days? Well, you can't. You can certainly do something pretty similar, though. That is, you can step into a stake in MercadoLibre (NASDAQ: MELI) -- which is often referred to as the Amazon of Latin America -- in front of what's increasingly looking like a boom for the region's e-commerce industry.

E-commerce has been around in South America for almost as long as it's been an industry in North America, to be clear. Its chief growth challenge there was mostly just a lack of consumer access to internet connectivity.

That's now changing, however, with one big difference between the two continents' internet businesses -- smartphones are the preferred means of shopping online in South America. MercadoLibre reports that 84% of the purchases its platform facilitates are made with a smartphone, in fact.

The end result is still the same. That is, the longer consumers and businesses continue connecting online there, the more both sides of the table want to do more of it. That's why Global Research expects Latin America's e-commerce market to grow by more than 12% per year through 2035.

Image source: Getty Images.

Now, anyone keeping tabs on this ticker likely already know that -- like Qualcomm -- MELI shares haven't performed well of late. Blame its heavy spending on free deliveries for most purchases made in its all-important Brazilian market, mostly. It's crimping profit margins.

Just don't lose sight of what's really happening here. Much like Amazon did in its early days, MercadoLibre's making a long-term investment in market share that's causing some short-term pain. Last quarter's and last year's year-over-year revenue growth of 44% and 39% (respectively) are the numbers you want to focus on, as they confirm that the company is turning a highly fragmented group of consumers into its own regular customers.

3. CRISPR Therapeutics

Last but not least, add CRISPR Therapeutics (NASDAQ: CRSP) to your list of potential monster stocks that could have a fantastic 10-year run.

It's not a household name, but noteworthy all the same. See, CRISPR Therapeutics was one of the very first biotechnology companies to create an FDA-approved gene therapy -- its Casgevy was approved in late 2023 as a treatment for sickle cell disease.

And it's going well, although administering it is a slow process, requiring cell samples from a patient that are then engineered and reinjected back into that same patient a few months later. It's also expensive, at a price of more than $2 million per patient. Even if it's ultimately covered by insurance, health insurers obviously aren't going to cover this cost without some degree of scrutiny. CRISPR Therapeutics also doesn't book Casgevy revenue right away, even if the treatment process has already begun.

It's coming, though. Nearly half of last year's Casgevy revenue of $116 million materialized in the fourth quarter of 2025 alone, as most of its earliest patients finally got their dosing. Developmental partner Vertex Pharmaceuticals adds that it foresees "$500 million or more in revenue from non-CF products, including increased patient infusions of Casgevy through Vertex's global ATC [authorized treatment centers] network" in 2026. That doesn't detail how much of this amount will actually come from Casgevy and benefit CRISPR Therapeutics. It does, however, paint a pretty bullish picture.

With all of that being said, the underlying idea to keep in mind here isn't Casgevy's potential as a treatment for sickle cell disease. Far more important is the fact that its continued acceptance proves gene therapies have their place within the pharma arena. Given CRISPR's five other gene-editing treatments in clinical trials right now plus a handful more in pre-clinical studies, Straits Research's belief that the global gene-editing business is poised to grow at an average annual pace of nearly 17% through 2033 means the next several years could be exciting ones for CRISPR Therapeutics to say the least.

Just bear in mind this company remains unprofitable, and likely will for a while. This could keep the stock volatile.

James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, CRISPR Therapeutics, MercadoLibre, Nvidia, Qualcomm, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.